{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T01:37:16Z","timestamp":1794879436420,"version":"4.9.1"},"reference-count":139,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parathyroid carcinoma (PC) is a rare malignancy accounting for &amp;lt;1% of primary hyperparathyroidism cases. This review summarizes current knowledge on its molecular pathogenesis, diagnosis, imaging, management and prognosis. PC is driven primarily by CDC73 mutations with loss of parafibromin expression, with emerging roles for PI3K\/AKT\/mTOR and Wnt pathway alterations. Its diagnosis remains challenging. Clinical suspicion should arise with marked hypercalcemia, elevated PTH, palpable neck mass or recurrent laryngeal nerve palsy. Imaging modalities including cervical ultrasound, 99mTc-sestamibi, 4D-CT, and [18F]fluorocholine PET\/CT aid localization and metastasis detection. En bloc resection with ipsilateral thyroid lobectomy is the standard approach. Traditional medical therapies are helpful in reducing serum calcium level. Radiotherapy and chemotherapy have limited efficacy. Targeted therapies and immunotherapy show promise in advanced disease, however, the such evidence is weak. Recurrence rates of 23% to 65% mandate lifelong follow-up. Prognostic factors include surgical approach, postoperative remission, Ki-67 index, as well as parafibromin status and mTOR activation. Multidisciplinary management in specialized centers is critical for optimizing outcomes.<\/jats:p>","DOI":"10.1210\/clinem\/dgag266","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:21:20Z","timestamp":1783084880000},"page":"3012-3031","source":"Crossref","is-referenced-by-count":2,"title":["Parathyroid carcinoma: from molecular pathogenesis to multidisciplinary management"],"prefix":"10.1210","volume":"111","author":[{"given":"Jia-xi","family":"Song","sequence":"first","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-ying","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-xin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao-ji","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Vascular Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-ting","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of General Practice, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bei","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Thyroid and Vascular Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-hao","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0179-1751","authenticated-orcid":false,"given":"Jian-min","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]},{"name":"Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai 200025 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"6","key":"2026101520045322700_dgag266-B1","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.3390\/cancers14061426","article-title":"Parathyroid carcinoma: incidence, survival analysis, and management: a study from the SEER database and insights into future therapeutic perspectives","volume":"14","author":"Ullah","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"4","key":"2026101520045322700_dgag266-B2","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-22-0287","article-title":"Diagnosis and management of parathyroid carcinoma: a state-of-the-art review","volume":"30","author":"Roser","year":"2023","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026101520045322700_dgag266-B3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1210\/jc.2012-2914","article-title":"The changing clinical patterns of primary hyperparathyroidism in Chinese patients: data from 2000 to 2010 in a single clinical center","volume":"98","author":"Zhao","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2026101520045322700_dgag266-B4","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.ecl.2021.07.001","article-title":"Parathyroid carcinoma and ectopic secretion of parathyroid hormone","volume":"50","author":"Cetani","year":"2021","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"2026101520045322700_dgag266-B5","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/s12022-022-09709-1","article-title":"Overview of the 2022 WHO classification of parathyroid tumors","volume":"33","author":"Erickson","year":"2022","journal-title":"Endocr Pathol"},{"issue":"1","key":"2026101520045322700_dgag266-B6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11864-011-0171-3","article-title":"Parathyroid carcinoma: update and guidelines for management","volume":"13","author":"Wei","year":"2012","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2026101520045322700_dgag266-B7","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12020-023-03376-w","article-title":"Parathyroid carcinoma: molecular therapeutic targets","volume":"81","author":"Marini","year":"2023","journal-title":"Endocrine"},{"issue":"2","key":"2026101520045322700_dgag266-B8","doi-asserted-by":"crossref","first-page":"E360","DOI":"10.1210\/jc.2014-3238","article-title":"Whole-exome sequencing studies of parathyroid carcinomas reveal novel PRUNE2 mutations, distinctive mutational spectra related to APOBEC-catalyzed DNA mutagenesis and mutational enrichment in kinases associated with cell migration and invasion","volume":"100","author":"Yu","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101520045322700_dgag266-B9","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1530\/EJE-21-0668","article-title":"Filamin A and parafibromin expression in parathyroid carcinoma","volume":"185","author":"Storvall","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2026101520045322700_dgag266-B10","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3390\/cancers15051405","article-title":"Novel PRUNE2 germline mutations in aggressive and benign parathyroid neoplasms","volume":"15","author":"Storvall","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"2","key":"2026101520045322700_dgag266-B11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1530\/ERC-20-0450","article-title":"Gene expression profile in metastatic and non-metastatic parathyroid carcinoma","volume":"28","author":"Condello","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026101520045322700_dgag266-B12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1530\/EC-13-0046","article-title":"CDC73 mutational status and loss of parafibromin in the outcome of parathyroid cancer","volume":"2","author":"Cetani","year":"2013","journal-title":"Endocr Connect"},{"issue":"7","key":"2026101520045322700_dgag266-B13","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s00268-014-2455-9","article-title":"Copy number variation in CCND1 gene is implicated in the pathogenesis of sporadic parathyroid carcinoma","volume":"38","author":"Zhao","year":"2014","journal-title":"World J Surg"},{"issue":"6","key":"2026101520045322700_dgag266-B14","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92061","article-title":"Genomic profiling reveals mutational landscape in parathyroid carcinomas","volume":"2","author":"Pandya","year":"2017","journal-title":"JCI Insight"},{"issue":"3","key":"2026101520045322700_dgag266-B15","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1210\/js.2018-00043","article-title":"Comprehensive genomic characterization of parathyroid cancer identifies novel candidate driver mutations and core pathways","volume":"3","author":"Clarke","year":"2019","journal-title":"J Endocr Soc"},{"issue":"5","key":"2026101520045322700_dgag266-B16","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1038\/s12276-023-00968-4","article-title":"Genomic and transcriptomic profiling reveal molecular characteristics of parathyroid carcinoma","volume":"55","author":"Jo","year":"2023","journal-title":"Exp Mol Med"},{"issue":"10","key":"2026101520045322700_dgag266-B17","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1210\/clinem\/dgaf042","article-title":"PI3K\/AKT\/mTOR activation is associated with malignant severity and poorer prognosis in parathyroid carcinomas","volume":"110","author":"Song","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101520045322700_dgag266-B18","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10360","article-title":"PIK3CA mutational analysis of parathyroid adenomas","volume":"4","author":"Riccardi","year":"2020","journal-title":"JBMR Plus"},{"key":"2026101520045322700_dgag266-B19","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.853171","article-title":"Germline mutations related to primary hyperparathyroidism identified by next-generation sequencing","volume":"13","author":"Park","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2026101520045322700_dgag266-B20","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1530\/ERC-13-0497","article-title":"The histone methyltransferase EZH2, an oncogene common to benign and malignant parathyroid tumors","volume":"21","author":"Svedlund","year":"2014","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"2026101520045322700_dgag266-B21","doi-asserted-by":"crossref","first-page":"646","DOI":"10.4161\/epi.24823","article-title":"Global and gene-specific promoter methylation analysis in primary hyperparathyroidism","volume":"8","author":"Sulaiman","year":"2013","journal-title":"Epigenetics"},{"issue":"9","key":"2026101520045322700_dgag266-B22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1002\/gcc.20895","article-title":"The DNA methylome of benign and malignant parathyroid tumors","volume":"50","author":"Starker","year":"2011","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"2026101520045322700_dgag266-B23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009472","article-title":"Frequent promoter hypermethylation of the APC and RASSF1A tumour suppressors in parathyroid tumours","volume":"5","author":"Juhlin","year":"2010","journal-title":"PLoS One"},{"issue":"7","key":"2026101520045322700_dgag266-B24","doi-asserted-by":"crossref","first-page":"E1307","DOI":"10.1210\/jc.2011-3136","article-title":"Hypermethylated in cancer 1 (HIC1), a tumor suppressor gene epigenetically deregulated in hyperparathyroid tumors by histone H3 lysine modification","volume":"97","author":"Svedlund","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2026101520045322700_dgag266-B25","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1677\/ERC-09-0134","article-title":"Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue","volume":"17","author":"Corbetta","year":"2010","journal-title":"Endocr Relat Cancer"},{"issue":"4","key":"2026101520045322700_dgag266-B26","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.284","article-title":"Serum circulating miRNA-342-3p as a potential diagnostic biomarker in parathyroid carcinomas: a pilot study","volume":"4","author":"Krupinova","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"issue":"4","key":"2026101520045322700_dgag266-B27","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40618-014-0234-y","article-title":"MicroRNA deregulation in parathyroid tumours suggests an embryonic signature","volume":"38","author":"Verdelli","year":"2015","journal-title":"J Endocrinol Invest"},{"key":"2026101520045322700_dgag266-B28","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.869006","article-title":"The long non-coding BC200 is a novel circulating biomarker of parathyroid carcinoma","volume":"13","author":"Morotti","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2026101520045322700_dgag266-B29","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1245\/s10434-015-4672-3","article-title":"Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB)","volume":"22","author":"Asare","year":"2015","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"2026101520045322700_dgag266-B30","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1038\/nrendo.2012.102","article-title":"Diagnosis and management of parathyroid cancer","volume":"8","author":"Schulte","year":"2012","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"2026101520045322700_dgag266-B31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/cen.13055","article-title":"Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients","volume":"85","author":"Xue","year":"2016","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"2026101520045322700_dgag266-B32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1007\/s40618-016-0447-3","article-title":"Update on parathyroid carcinoma","volume":"39","author":"Cetani","year":"2016","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2026101520045322700_dgag266-B33","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1210\/clinem\/dgad455","article-title":"Approach to the patient with parathyroid carcinoma","volume":"109","author":"Cetani","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"2026101520045322700_dgag266-B34","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/bjs\/znac006","article-title":"Life expectancy and likelihood of surgery in multiple endocrine neoplasia type 1: AFCE and GTE cohort study","volume":"109","author":"Gaujoux","year":"2022","journal-title":"Br J Surg"},{"issue":"Suppl 2","key":"2026101520045322700_dgag266-B35","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1038\/modpathol.2010.133","article-title":"Follicular thyroid carcinoma","volume":"24","author":"Sobrinho-Simoes","year":"2011","journal-title":"Mod Pathol"},{"issue":"5","key":"2026101520045322700_dgag266-B36","doi-asserted-by":"crossref","DOI":"10.1093\/bjs\/znae108","article-title":"Consensus statement of the European Society of Endocrine Surgeons (ESES) on advanced parathyroid cancer: definitions and management","volume":"111","author":"Makay","year":"2024","journal-title":"Br J Surg"},{"issue":"5","key":"2026101520045322700_dgag266-B37","first-page":"361","article-title":"Expert consensus on the management of parathyroid carcinoma","volume":"35","author":"Society of Parathyroid and Metabolic Bone Diseases","year":"2019","journal-title":"Chin J. Endocrinol. Metabol"},{"issue":"7","key":"2026101520045322700_dgag266-B38","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/0284186X.2017.1306103","article-title":"A nationwide study on parathyroid carcinoma","volume":"56","author":"Ryhanen","year":"2017","journal-title":"Acta Oncol"},{"issue":"1","key":"2026101520045322700_dgag266-B39","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00268-010-0826-4","article-title":"Parathyroid carcinoma encountered after minimally invasive focused parathyroidectomy may not require further radical surgery","volume":"35","author":"O'Neill","year":"2011","journal-title":"World J Surg"},{"issue":"8","key":"2026101520045322700_dgag266-B40","doi-asserted-by":"crossref","first-page":"890","DOI":"10.3346\/jkms.2012.27.8.890","article-title":"Preoperative predictive factors for parathyroid carcinoma in patients with primary hyperparathyroidism","volume":"27","author":"Bae","year":"2012","journal-title":"J Korean Med Sci"},{"issue":"6","key":"2026101520045322700_dgag266-B41","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jamcollsurg.2014.10.007","article-title":"Modern experience with aggressive parathyroid tumors in a high-volume New England referral center","volume":"220","author":"Quinn","year":"2015","journal-title":"J Am Coll Surg"},{"issue":"3","key":"2026101520045322700_dgag266-B42","doi-asserted-by":"crossref","first-page":"E453","DOI":"10.1210\/jc.2013-3730","article-title":"The third\/second generation PTH assay ratio as a marker for parathyroid carcinoma: evaluation using an automated platform","volume":"99","author":"Cavalier","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2026101520045322700_dgag266-B43","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/j.surg.2014.08.069","article-title":"Parathyroid carcinoma in more than 1,000 patients: a population-level analysis","volume":"156","author":"Sadler","year":"2014","journal-title":"Surgery"},{"key":"2026101520045322700_dgag266-B44","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112329","article-title":"Advances in the management of parathyroid carcinoma","volume":"592","author":"Kubal","year":"2024","journal-title":"Mol Cell Endocrinol"},{"issue":"9","key":"2026101520045322700_dgag266-B45","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1245\/s10434-016-5248-6","article-title":"Differentiating atypical parathyroid neoplasm from parathyroid cancer","volume":"23","author":"Christakis","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"2026101520045322700_dgag266-B46","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1007\/s00268-012-1707-9","article-title":"Development of a formula to predict parathyroid carcinoma in patients with primary hyperparathyroidism","volume":"36","author":"Karakas","year":"2012","journal-title":"World J Surg"},{"issue":"1","key":"2026101520045322700_dgag266-B47","doi-asserted-by":"crossref","first-page":"19007","DOI":"10.1038\/s41598-023-46294-7","article-title":"Machine learning-based prediction models for parathyroid carcinoma using pre-surgery cognitive function and clinical features","volume":"13","author":"Wang","year":"2023","journal-title":"Sci Rep"},{"issue":"7","key":"2026101520045322700_dgag266-B48","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1245\/ASO.2005.06.005","article-title":"Primary hyperparathyroidism: can parathyroid carcinoma be anticipated on clinical and biochemical grounds? Report of nine cases and review of the literature","volume":"12","author":"Robert","year":"2005","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"2026101520045322700_dgag266-B49","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1530\/EJE-08-0169","article-title":"Human chorionic gonadotropin measurements in parathyroid carcinoma","volume":"159","author":"Rubin","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2026101520045322700_dgag266-B50","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0192","article-title":"Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma","volume":"32","author":"Xiao","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026101520045322700_dgag266-B51","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s12020-024-03831-2","article-title":"Detection and identification of circulating tumor cells in parathyroid tumors and correlation analysis with clinicopathological features","volume":"85","author":"Wang","year":"2024","journal-title":"Endocrine"},{"issue":"11","key":"2026101520045322700_dgag266-B52","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.3390\/cancers11111676","article-title":"Parathyroid cancer: a review","volume":"11","author":"Machado","year":"2019","journal-title":"Cancers (Basel)"},{"key":"2026101520045322700_dgag266-B53","article-title":"Parathyroid imaging: past, present, and future","volume":"12","author":"Morris","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2026101520045322700_dgag266-B54","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1007\/s00259-021-05334-y","article-title":"The EANM practice guidelines for parathyroid imaging","volume":"48","author":"Ovcaricek P","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"2026101520045322700_dgag266-B55","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.crad.2009.12.005","article-title":"Clinical utility of ultrasound and 99mTc sestamibi SPECT\/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism","volume":"65","author":"Patel","year":"2010","journal-title":"Clin Radiol"},{"issue":"8","key":"2026101520045322700_dgag266-B56","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.21037\/qims.2019.07.02","article-title":"Semi-quantitative analysis of (99m)Tc-sestamibi retention level for preoperative differential diagnosis of parathyroid carcinoma","volume":"9","author":"Zhang","year":"2019","journal-title":"Quant Imaging Med Surg"},{"issue":"8","key":"2026101520045322700_dgag266-B57","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1007\/s00259-025-07162-w","article-title":"Parathyroid carcinoma: a comprehensive analysis with focus on molecular imaging","volume":"52","author":"Ovcaricek P","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026101520045322700_dgag266-B58","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/3108395","article-title":"Factors that affect the sensitivity of imaging modalities in primary hyperparathyroidism","volume":"2021","author":"Zhu","year":"2021","journal-title":"Int J Endocrinol"},{"key":"2026101520045322700_dgag266-B59","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejrad.2017.07.026","article-title":"The diagnostic accuracy of neck ultrasound, 4D-computed tomography and sestamibi imaging in parathyroid carcinoma","volume":"95","author":"Christakis","year":"2017","journal-title":"Eur J Radiol"},{"issue":"5","key":"2026101520045322700_dgag266-B60","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s11604-019-00825-3","article-title":"CT features of parathyroid carcinomas: comparison with benign parathyroid lesions","volume":"37","author":"Takumi","year":"2019","journal-title":"Jpn J Radiol"},{"issue":"14","key":"2026101520045322700_dgag266-B61","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.3390\/cancers16142593","article-title":"Imaging recommendations for diagnosis and management of primary parathyroid pathologies: a comprehensive review","volume":"16","author":"Chakrabarty","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"14","key":"2026101520045322700_dgag266-B62","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/diagnostics14141548","article-title":"Dual-tracer positron emission tomography\/computed tomography with [(18)F]FDG and [(18)F]fluorocholine in a patient with metastatic parathyroid carcinoma","volume":"14","author":"Iacovitti","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"2026101520045322700_dgag266-B63","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.982972","article-title":"Diagnosis and treatment of liver metastases of parathyroid carcinoma","volume":"13","author":"Su","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026101520045322700_dgag266-B64","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/cpt.3432","article-title":"Diagnosis and management of parathyroid carcinoma","volume":"116","author":"Lazzaro","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"2026101520045322700_dgag266-B65","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/01455613211016703","article-title":"Oligometastatic parathyroid carcinoma presenting as neck pain: a case report","volume":"102","author":"Yu","year":"2023","journal-title":"Ear Nose Throat J"},{"issue":"4","key":"2026101520045322700_dgag266-B66","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjoto.2023.103843","article-title":"Parathyroid carcinoma: current management and outcomes - A systematic review","volume":"44","author":"McInerney","year":"2023","journal-title":"Am J Otolaryngol"},{"issue":"1","key":"2026101520045322700_dgag266-B67","first-page":"56","article-title":"Parathyroid carcinoma\u2014a study of 29 cases","volume":"73","author":"Kowalski","year":"2022","journal-title":"Endokrynol Pol"},{"issue":"7","key":"2026101520045322700_dgag266-B68","doi-asserted-by":"crossref","first-page":"634","DOI":"10.4158\/EP-2018-0538","article-title":"The influence of surgical extent and parafibromin staining on the outcome of parathyroid carcinoma: 20-year experience from a single institute","volume":"25","author":"Hu","year":"2019","journal-title":"Endocr Pract"},{"issue":"11","key":"2026101520045322700_dgag266-B69","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.ejso.2021.06.026","article-title":"Local resection versus radical surgery for parathyroid carcinoma: a National Cancer Database analysis","volume":"47","author":"Leonard-Murali","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"2026101520045322700_dgag266-B70","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jss.2023.11.074","article-title":"A &gt;50% intraoperative parathyroid hormone level decrease into normal reference range predicts complete excision of malignancy in patients with parathyroid carcinoma","volume":"300","author":"Armstrong","year":"2024","journal-title":"J Surg Res"},{"issue":"10","key":"2026101520045322700_dgag266-B71","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103664","article-title":"Neuroendocrine neoplasms of head and neck, genitourinary and gynaecological systems, unknown primaries, parathyroid carcinomas and intrathyroid thymic neoplasms: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"9","author":"Hadoux","year":"2024","journal-title":"ESMO Open"},{"issue":"6","key":"2026101520045322700_dgag266-B72","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.21037\/gs-21-50","article-title":"Bilateral axillo-breast approach robotic thyroidectomy: review of a single surgeon's consecutive 317 cases","volume":"10","author":"You","year":"2021","journal-title":"Gland Surg"},{"issue":"3","key":"2026101520045322700_dgag266-B73","doi-asserted-by":"crossref","first-page":"953","DOI":"10.21037\/gs-20-761","article-title":"Robotic-assisted parathyroidectomy via transaxillary approach: feasibility and learning curves","volume":"10","author":"Kandil","year":"2021","journal-title":"Gland Surg"},{"issue":"11","key":"2026101520045322700_dgag266-B74","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1210\/js.2019-00175","article-title":"MGMT promoter methylation and parathyroid carcinoma","volume":"3","author":"Storvall","year":"2019","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2026101520045322700_dgag266-B75","doi-asserted-by":"crossref","first-page":"A1008","DOI":"10.1210\/jendso\/bvab048.2062","article-title":"Use of temozolomide in parathyroid carcinoma with negative mgmt promoter methylation","volume":"5","author":"Reddy","year":"2021","journal-title":"J Endocr Soc"},{"issue":"1","key":"2026101520045322700_dgag266-B76","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1245\/s10434-020-08825-8","article-title":"The use and benefit of adjuvant radiotherapy in parathyroid carcinoma: a national cancer database analysis","volume":"28","author":"Limberg","year":"2021","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"2026101520045322700_dgag266-B77","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American Association of Endocrine Surgeons guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","journal-title":"JAMA Surg"},{"issue":"1","key":"2026101520045322700_dgag266-B78","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/COC.0b013e31823a4924","article-title":"High index of clinical suspicion with optimal surgical techniques and adjuvant radiotherapy is critical to reduce locoregional disease progression in parathyroid carcinoma","volume":"36","author":"Selvan","year":"2013","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"2026101520045322700_dgag266-B79","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/cncr.11819","article-title":"Parathyroid carcinoma: is there a role for adjuvant radiation therapy?","volume":"98","author":"Munson","year":"2003","journal-title":"Cancer"},{"issue":"1","key":"2026101520045322700_dgag266-B80","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ejso.2004.06.014","article-title":"One stage treatment of parathyroid cancer","volume":"31","author":"Kirkby-Bott","year":"2005","journal-title":"Eur J Surg Oncol"},{"issue":"1","key":"2026101520045322700_dgag266-B81","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s42000-020-00220-y","article-title":"Seven cases of parathyroid carcinoma and review of the literature","volume":"20","author":"Apaydin","year":"2021","journal-title":"Hormones (Athens)"},{"issue":"22","key":"2026101520045322700_dgag266-B82","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.2169\/internalmedicine.9261-21","article-title":"Successful control of hypercalcemia with sorafenib, evocalcet, and denosumab combination therapy for recurrent parathyroid carcinoma","volume":"61","author":"Makino","year":"2022","journal-title":"Intern Med"},{"key":"2026101520045322700_dgag266-B83","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3389\/fendo.2019.00731","article-title":"The clinicopathological spectrum of parathyroid carcinoma","volume":"10","author":"Akirov","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"8","key":"2026101520045322700_dgag266-B84","article-title":"Sporadic parathyroid carcinoma treated with lenvatinib, exhibiting a novel somatic MEN1 mutation","volume":"2","author":"Ito","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"17","key":"2026101520045322700_dgag266-B85","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e36656","article-title":"Efficacy of surufatinib in the treatment of advanced parathyroid carcinoma: a case report","volume":"10","author":"Yu","year":"2024","journal-title":"Heliyon"},{"issue":"7","key":"2026101520045322700_dgag266-B86","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/1878-0261.13398","article-title":"Targeted therapy of advanced parathyroid carcinoma guided by genomic and transcriptomic profiling","volume":"17","author":"Teleanu","year":"2023","journal-title":"Mol Oncol"},{"issue":"7","key":"2026101520045322700_dgag266-B87","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241259669","article-title":"Long-term survival in a patient with metastatic parathyroid carcinoma harboring an EGFR sensitizing mutation: a case report","volume":"52","author":"Ying","year":"2024","journal-title":"J Int Med Res"},{"key":"2026101520045322700_dgag266-B88","doi-asserted-by":"crossref","first-page":"641","DOI":"10.3389\/fendo.2018.00641","article-title":"Intrathyroidal parathyroid carcinoma: an atypical thyroid lesion","volume":"9","author":"Alharbi","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026101520045322700_dgag266-B89","doi-asserted-by":"crossref","DOI":"10.1177\/11795514251372695","article-title":"Biochemical and structural response to lenvatinib in metastatic parathyroid carcinoma: case report","volume":"18","author":"Rivera","year":"2025","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"8","key":"2026101520045322700_dgag266-B90","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1007\/s00432-019-02945-9","article-title":"Genetic profiling as a clinical tool in advanced parathyroid carcinoma","volume":"145","author":"Kutahyalioglu","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026101520045322700_dgag266-B91","article-title":"Diagnosis and treatment challenges of parathyroid carcinoma in a 27-year-old woman with multiple lung metastases","volume":"2017","author":"Rozhinskaya","year":"2017","journal-title":"Endocrinol Diabetes Metab Case Rep"},{"issue":"12","key":"2026101520045322700_dgag266-B92","article-title":"Successful multimodal treatment of locally advanced parathyroid carcinoma","volume":"2","author":"Kim","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"6","key":"2026101520045322700_dgag266-B93","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ando.2023.06.003","article-title":"Parathyroid cancer with MTOR gene mutation: case report and review of the literature","volume":"84","author":"Stark","year":"2023","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"2026101520045322700_dgag266-B94","article-title":"Use of olaparib in the management of metastatic parathyroid carcinoma with BRCA1 mutation","volume":"3","author":"Woodfield","year":"2025","journal-title":"JCEM Case Rep"},{"issue":"1","key":"2026101520045322700_dgag266-B95","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/1476-4598-7-65","article-title":"The parafibromin tumor suppressor protein interacts with actin-binding proteins actinin-2 and actinin-3","volume":"7","author":"Agarwal","year":"2008","journal-title":"Mol Cancer"},{"issue":"1","key":"2026101520045322700_dgag266-B96","doi-asserted-by":"crossref","first-page":"5433","DOI":"10.1038\/ncomms6433","article-title":"Cytoplasmic parafibromin\/hCdc73 targets and destabilizes p53 mRNA to control p53-mediated apoptosis","volume":"5","author":"Jo","year":"2014","journal-title":"Nat Commun"},{"issue":"5","key":"2026101520045322700_dgag266-B97","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.surg.2018.06.013","article-title":"Characterizing parathyroid carcinomas and atypical neoplasms based on the expression of programmed death-ligand 1 expression and the presence of tumor-infiltrating lymphocytes and macrophages","volume":"164","author":"Silva-Figueroa","year":"2018","journal-title":"Surgery"},{"issue":"7","key":"2026101520045322700_dgag266-B98","article-title":"Refractory hypercalcemia secondary to metastatic parathyroid carcinoma treated with immunotherapy","volume":"2","author":"Ta","year":"2024","journal-title":"JCEM Case Rep"},{"issue":"11","key":"2026101520045322700_dgag266-B99","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1507\/endocrj.EJ24-0126","article-title":"Pembrolizumab with external radiation therapy effectively controlled TMB-high unresectable recurrent parathyroid cancer: a case report with review of literature","volume":"71","author":"Katoh","year":"2024","journal-title":"Endocr J"},{"key":"2026101520045322700_dgag266-B100","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.643328","article-title":"Case report: abdominal lymph node metastases of parathyroid carcinoma: diagnostic workup, molecular diagnosis, and clinical management","volume":"12","author":"Lenschow","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"9","key":"2026101520045322700_dgag266-B101","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2020-235293","article-title":"Microsatellite instability driven metastatic parathyroid carcinoma managed with the anti-PD1 immunotherapy, pembrolizumab","volume":"13","author":"Park","year":"2020","journal-title":"BMJ Case Rep"},{"issue":"4","key":"2026101520045322700_dgag266-B102","article-title":"Treating microsatellite unstable metastatic parathyroid carcinoma with anti-PD1 therapy","volume":"4","author":"Amir-Kabirian","year":"2026","journal-title":"JCEM Case Rep"},{"issue":"9","key":"2026101520045322700_dgag266-B103","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1210\/jc.2013-2014","article-title":"Unusual case of solitary functioning bone metastasis from a \u201cparathyroid adenoma\u201d: imagiologic diagnosis and treatment with percutaneous vertebroplasty\u2013case report and literature review","volume":"98","author":"Qiu","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2026101520045322700_dgag266-B104","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.jvir.2007.12.440","article-title":"Radiofrequency ablation of functioning lung metastases from parathyroid carcinoma","volume":"19","author":"Iguchi","year":"2008","journal-title":"J Vasc Interv Radiol"},{"key":"2026101520045322700_dgag266-B105","article-title":"Hypercalcemia of malignancy revealing a parathyroid carcinoma with hepatic metastasis: a case report and literature review","volume":"2020","author":"Mellagui","year":"2020","journal-title":"Case Rep Surg"},{"issue":"5","key":"2026101520045322700_dgag266-B106","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11864-022-00967-z","article-title":"New PET radiotracers for the imaging of neuroendocrine neoplasms","volume":"23","author":"Fortunati","year":"2022","journal-title":"Curr Treat Options Oncol"},{"issue":"3","key":"2026101520045322700_dgag266-B107","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1210\/clinem\/dgac621","article-title":"Treatment of hypercalcemia of malignancy in adults: an Endocrine Society clinical practice guideline","volume":"108","author":"El-Hajj Fuleihan","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2026101520045322700_dgag266-B108","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2024.101966","article-title":"Parathyroid carcinoma: new insights","volume":"39","author":"Viswanath","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"1","key":"2026101520045322700_dgag266-B109","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","article-title":"Denosumab in the treatment of osteoporosis: 10 years later: a narrative review","volume":"39","author":"Kendler","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"2026101520045322700_dgag266-B110","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s12022-018-9527-6","article-title":"Immunohistochemistry in diagnostic parathyroid pathology","volume":"29","author":"Erickson","year":"2018","journal-title":"Endocr Pathol"},{"issue":"7","key":"2026101520045322700_dgag266-B111","doi-asserted-by":"crossref","first-page":"R441","DOI":"10.1530\/ERC-19-0135","article-title":"Atypical parathyroid adenomas: challenging lesions in the differential diagnosis of endocrine tumors","volume":"26","author":"Cetani","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2026101520045322700_dgag266-B112","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/0046-8177(95)90028-4","article-title":"Proliferative activity in parathyroid tumors as detected by ki-67 immunostaining","volume":"26","author":"Abbona","year":"1995","journal-title":"Hum Pathol"},{"issue":"4","key":"2026101520045322700_dgag266-B113","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s12022-019-09592-3","article-title":"Using a novel diagnostic nomogram to differentiate malignant from benign parathyroid neoplasms","volume":"30","author":"Silva-Figueroa","year":"2019","journal-title":"Endocr Pathol"},{"issue":"2","key":"2026101520045322700_dgag266-B114","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s12022-019-9578-3","article-title":"Parathyroid neoplasms: immunohistochemical characterization and long noncoding RNA (lncRNA) expression","volume":"30","author":"Yu","year":"2019","journal-title":"Endocr Pathol"},{"issue":"4","key":"2026101520045322700_dgag266-B115","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng1048","article-title":"HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome","volume":"32","author":"Carpten","year":"2002","journal-title":"Nat Genet"},{"issue":"8","key":"2026101520045322700_dgag266-B116","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1038\/s41379-019-0252-6","article-title":"Parafibromin immunostainings of parathyroid tumors in clinical routine: a near-decade experience from a tertiary center","volume":"32","author":"Juhlin","year":"2019","journal-title":"Mod Pathol"},{"issue":"2","key":"2026101520045322700_dgag266-B117","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1245\/s10434-013-3288-8","article-title":"Negative parafibromin staining predicts malignant behavior in atypical parathyroid adenomas","volume":"21","author":"Kruijff","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2026101520045322700_dgag266-B118","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13402-012-0100-x","article-title":"CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: clinical correlations in a single-centre patient cohort","volume":"35","author":"Guarnieri","year":"2012","journal-title":"Cell Oncol (Dordr)"},{"issue":"2","key":"2026101520045322700_dgag266-B119","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1677\/ERC-07-0021","article-title":"Parafibromin immunoreactivity: its use as an additional diagnostic marker for parathyroid tumor classification","volume":"14","author":"Juhlin","year":"2007","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"2026101520045322700_dgag266-B120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12022-010-9121-z","article-title":"Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas","volume":"21","author":"Juhlin","year":"2010","journal-title":"Endocr Pathol"},{"issue":"9","key":"2026101520045322700_dgag266-B121","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1245\/s10434-018-6559-6","article-title":"Tumor size and presence of metastatic disease at diagnosis are associated with disease-specific survival in parathyroid carcinoma","volume":"25","author":"Lo","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"9","key":"2026101520045322700_dgag266-B122","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1007\/s00405-022-07403-w","article-title":"Tumor size rather than the thyroid invasion affects the prognosis of parathyroid carcinoma without lymph node or distant metastasis","volume":"279","author":"Sun","year":"2022","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"8","key":"2026101520045322700_dgag266-B123","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1245\/s10434-010-1003-6","article-title":"Clinical presentation, staging and long-term evolution of parathyroid cancer","volume":"17","author":"Talat","year":"2010","journal-title":"Ann Surg Oncol"},{"key":"2026101520045322700_dgag266-B124","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.766234","article-title":"Spontaneous remission after a hypercalcemic crisis caused by an intracystic hemorrhage of bilateral parathyroid adenomas: a case report and literature review","volume":"12","author":"Liu","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"2026101520045322700_dgag266-B125","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.surg.2007.09.014","article-title":"Functional parathyroid carcinoma: long-term treatment outcome and risk factor analysis","volume":"142","author":"Iihara","year":"2007","journal-title":"Surgery"},{"issue":"6","key":"2026101520045322700_dgag266-B126","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/jso.24407","article-title":"Oncologic progress for the treatment of parathyroid carcinoma is needed","volume":"114","author":"Christakis","year":"2016","journal-title":"J Surg Oncol"},{"issue":"Suppl 1","key":"2026101520045322700_dgag266-B127","doi-asserted-by":"crossref","first-page":"S94","DOI":"10.1016\/j.ijsu.2015.12.040","article-title":"Controversies in the management of parathyroid carcinoma: a case series and review of the literature","volume":"28","author":"Medas","year":"2016","journal-title":"Int J Surg"},{"key":"2026101520045322700_dgag266-B128","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1278178","article-title":"Management and surgical treatment of parathyroid carcinoma: a 6-year experience of a single centre of endocrine surgery unit","volume":"14","author":"Laforgia","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2026101520045322700_dgag266-B129","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1007\/s00259-015-3130-6","article-title":"(1)(8)Fluorocholine PET\/CT in parathyroid carcinoma: a new tool for disease staging?","volume":"42","author":"Deandreis","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"2026101520045322700_dgag266-B130","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/RLU.0000000000001652","article-title":"18F-Fluorocholine, 18F-FDG, and 18F-fluoroethyl tyrosine PET\/CT in parathyroid cancer","volume":"42","author":"Hatzl","year":"2017","journal-title":"Clin Nucl Med"},{"issue":"8","key":"2026101520045322700_dgag266-B131","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archsurg.136.8.878","article-title":"Localization and reoperation results for persistent and recurrent parathyroid carcinoma","volume":"136","author":"Kebebew","year":"2001","journal-title":"Arch Surg"},{"issue":"2","key":"2026101520045322700_dgag266-B132","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1097\/SLA.0000000000004144","article-title":"Clinical presentation, treatment, and outcome of parathyroid carcinoma: results of the NEKAR Retrospective International Multicenter Study","volume":"275","author":"Lenschow","year":"2022","journal-title":"Ann Surg"},{"issue":"4","key":"2026101520045322700_dgag266-B133","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/cen.14161","article-title":"Prognostic role of parafibromin staining and CDC73 mutation in patients with parathyroid carcinoma: a systematic review and meta-analysis based on individual patient data","volume":"92","author":"Zhu","year":"2020","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2026101520045322700_dgag266-B134","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s13023-025-03608-4","article-title":"The prognostic value of ultrasound features and parafibromin expression in parathyroid carcinoma","volume":"20","author":"Liu","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2026101520045322700_dgag266-B135","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1007\/s00432-021-03576-9","article-title":"Epidemiology and prognosis of parathyroid carcinoma: real-world data using nationwide cohort","volume":"147","author":"Kong","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"2026101520045322700_dgag266-B136","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.784599","article-title":"Prognostic analysis for patients with parathyroid carcinoma: a population-based study","volume":"16","author":"Qian","year":"2022","journal-title":"Front Neurosci"},{"issue":"2","key":"2026101520045322700_dgag266-B137","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1245\/s10434-021-10962-7","article-title":"Extended en bloc reoperation for recurrent or persistent parathyroid carcinoma: analysis of 31 cases in a single institute experience","volume":"29","author":"Wei","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2026101520045322700_dgag266-B138","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.13561","article-title":"Diabetes and gastric cancer incidence and mortality in the Asia cohort consortium: a pooled analysis of more than a half million participants","volume":"16","author":"De la Torre","year":"2024","journal-title":"J Diabetes"},{"issue":"4","key":"2026101520045322700_dgag266-B139","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-8587(25)00396-1","article-title":"Risk of recurrence after successful surgery for Cushing's disease and association with USP8 genotype and tumour size: an international, retrospective, longitudinal cohort study","volume":"14","author":"Zhang","year":"2026","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgag266\/68695734\/dgag266.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/3012\/68695734\/dgag266.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/111\/11\/3012\/68695734\/dgag266.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:05:12Z","timestamp":1792109112000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/111\/11\/3012\/8724726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":139,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,7,4]]},"published-print":{"date-parts":[[2026,10,16]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgag266","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,7,4]]}}}